(Drug Name) (Drug Form) (Drug Strength)
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • myWeekly Ad

ZYDELIG: Oral tablet (150mg)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file default-drug-image.png


What is this Medicine?

IDELALISIB (eye del AL isib) is a chemotherapy drug. It targets proteins in cancer cells and stops the cancer cells from growing.

In-Depth Information

Zydelig 150mg Tablet

NDC: 619581702
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL)

Storage Information
Store between 68 to 86 degrees F
Zydelig 150mg Tablet

Reported Side Effects for Zydelig 150mg Tablet

Sinus Infection Incidence:
<8.0%*
Severity: MILD
Onset: DELAYED
Mouth Ulcers Incidence:
<2.0%*
Severity: SEVERE
Onset: DELAYED
Low Platelet Count Incidence:
<6.0%*
Severity: SEVERE
Onset: DELAYED
Stomach Pain Incidence:
<2.0%*
Severity: SEVERE
Onset: EARLY
Hole In Intestines Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Increased Blood Sugar Incidence:
<7.0%*
Severity: SEVERE
Onset: DELAYED
Fluid Retention Incidence:
<2.0%*
Severity: SEVERE
Onset: DELAYED
Vomiting Incidence:
<1.0%*
Severity: SEVERE
Onset: EARLY
Anaphylactoid Reactions Incidence:
<1.0%*
Severity: SEVERE
Onset: RAPID
Weakness Incidence:
<2.0%*
Severity: SEVERE
Onset: DELAYED
Chills Incidence:
<2.0%*
Severity: SEVERE
Onset: RAPID
Heartburn Incidence:
<7.0%*
Severity: MILD
Onset: DELAYED
High Lymphocytes Incidence:
<18.0%*
Severity: SEVERE
Onset: DELAYED
Low Lymphocytes Incidence:
<9.0%*
Severity: SEVERE
Onset: DELAYED
Lyell'S Syndrome Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Upset Stomach Incidence:
<1.0%*
Severity: SEVERE
Onset: EARLY
Anemia Incidence:
<2.0%*
Severity: SEVERE
Onset: DELAYED
Decreased Appetite Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Joint Pain Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Cough Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Shortness Of Breath Incidence:
<4.0%*
Severity: SEVERE
Onset: EARLY
Tired Incidence:
<1.0%*
Severity: SEVERE
Onset: EARLY
High Triglycerides Incidence:
<3.0%*
Severity: SEVERE
Onset: DELAYED
Low Blood Sodium Levels Incidence:
<2.0%*
Severity: SEVERE
Onset: DELAYED
Inability To Sleep Incidence:
<12.0%*
Severity: MILD
Onset: EARLY
Stuffy Nose Incidence:
<5.0%*
Severity: MILD
Onset: EARLY
Headache Incidence:
1.0%*
Severity: SEVERE
Onset: EARLY
Fever Incidence:
2.0-3.0%*
Severity: SEVERE
Onset: EARLY
Elevated Hepatic Enzymes Incidence:
2.0-19.0%*
Severity: SEVERE
Onset: DELAYED
Skin Rash Incidence:
3.0-4.0%*
Severity: SEVERE
Onset: EARLY
Loose Stools Incidence:
5.0-14.0%*
Severity: SEVERE
Onset: EARLY
Lung Inflammation Incidence:
16.0%*
Severity: SEVERE
Onset: DELAYED
Low White Blood Cells Incidence:
25.0-37.0%*
Severity: SEVERE
Onset: DELAYED
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Pregnancy & Lactation Information
FIRST Trimester

Class D - Adequate well-controlled or observational studies in pregnant women have demonstrated a risk to the fetus. However, the benefits of therapy may outweigh the potential risk. For example, the drug may be acceptable if needed in a life-threatening situation or serious disease for which safer drugs cannot be used or are ineffective.

SECOND Trimester

Class D - Adequate well-controlled or observational studies in pregnant women have demonstrated a risk to the fetus. However, the benefits of therapy may outweigh the potential risk. For example, the drug may be acceptable if needed in a life-threatening situation or serious disease for which safer drugs cannot be used or are ineffective.

THIRD Trimester

Class D - Adequate well-controlled or observational studies in pregnant women have demonstrated a risk to the fetus. However, the benefits of therapy may outweigh the potential risk. For example, the drug may be acceptable if needed in a life-threatening situation or serious disease for which safer drugs cannot be used or are ineffective.

Lactation

Caution - Not enough information is available to rule out harm to infants when this drug is taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with ZYDELIG

Be the first to share your experience!

We want to help our customers stay educated about the medications they are taking. Submit your own observations and experiences to benefit others.

Average Scores
Easy to Take 
0 / 5
0 / 5
Works as Intended 
0 / 5
0 / 5
Tolerable 
0 / 5
0 / 5